Top

Published in:

01-01-2019 | What's New in Intensive Care

Ten things ICU specialists need to know about direct oral anticoagulants (DOACs)

Authors: Jakob Stensballe, Morten Hylander Møller

Published in: Intensive Care Medicine | Issue 1/2019

Excerpt

Anticoagulation is the cornerstone in the treatment of thromboembolic disorders. In the intensive care unit (ICU), anticoagulation is often challenging as the balance between bleeding and thrombosis is subtle, and anticoagulation-induced bleeding is associated with adverse outcome [1]. In this paper, we outline ten important things ICU specialists need to know about patients treated with direct oral anticoagulants (DOACs) …

Hunt BJ (2014) Bleeding and coagulopathies in critical care. N Engl J Med 370:847–859CrossRefPubMed

Lopez-Lopez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savovic J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R (2017) Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 359:j5058CrossRefPubMedPubMedCentral

Sterne JA, Bodalia PN, Bryden PA, Davies PA, Lopez-Lopez JA, Okoli GN, Thom HH, Caldwell DM, Dias S, Eaton D, Higgins JP, Hollingworth W, Salisbury C, Savovic J, Sofat R, Stephens-Boal A, Welton NJ, Hingorani AD (2017) Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 21:1–386CrossRefPubMedPubMedCentral

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messe SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol 70:3042–3067CrossRefPubMed

Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, Porte RJ, Lisman T (2014) Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 9:e88390CrossRefPubMedPubMedCentral

Lyons PG, Micek ST, Hampton N, Kollef MH (2018) Sepsis-associated coagulopathy severity predicts hospital mortality. Crit Care Med. https://doi.org/10.1097/CCM.0000000000002997 CrossRefPubMedPubMedCentral

Johansson PI, Stensballe J, Vindelov N, Perner A, Espersen K (2010) Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis 21:168–174CrossRefPubMed

Jensen KOF, Hansen SH, Goetze JP, Jesting A, Stensballe J, Hansen H (2017) Preliminary report: measurement of apixaban and rivaroxaban in plasma from bleeding patients. Eur J Haematol 99:431–436CrossRefPubMed

Solbeck S, Jensen AS, Maschmann C, Stensballe J, Ostrowski SR, Johansson PI (2018) The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG^®), hemoclot thrombin inhibitor (HTI) assay and ecarin clotting time (ECT). Scand J Clin Lab Invest 78:25–30CrossRefPubMed

10.

Dias JD, Norem K, Doorneweerd DD, Thurer RL, Popovsky MA, Omert LA (2015) Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med 139:665–673CrossRefPubMed

11.

Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg HK, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. https://doi.org/10.1093/europace/euy054 CrossRefPubMed

12.

Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108:217–224CrossRefPubMed

13.

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI (2017) Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 377:431–441CrossRefPubMed

14.

Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, Frost C (2014) Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 14:147–154CrossRefPubMed

15.

Stangier J, Rathgen K, Stahle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259–268CrossRefPubMed

16.

Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, Ker K (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 16(3):001886

17.

Beitland S, Sandven I, Kjaervik LK, Sandset PM, Sunde K, Eken T (2015) Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 41:1209–1219CrossRefPubMed

Title: Ten things ICU specialists need to know about direct oral anticoagulants (DOACs)
Authors: Jakob Stensballe
Morten Hylander Møller
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 1/2019
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-018-5192-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Ten things ICU specialists need to know about direct oral anticoagulants (DOACs)

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

Scorpion envenomation: from a neglected to a helpful disease?

Correction to: What's new in immunostimulating strategies in the ICU

Her ICU bed

Academic conflict of interest

Paediatric acute kidney injury: can we match therapy with resources around the world?

Understanding central nervous system efficacy of antimicrobials